TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Tenon Medical, Inc. ( (TNON) ) is now available.
On November 10, 2025, Tenon Medical, Inc. entered into securities purchase agreements with accredited investors to issue 2,217,904 shares of common stock and warrants, raising approximately $2.85 million. The offering, which closed on November 14, 2025, aims to support working capital, corporate purposes, and the company’s growth strategy, including product launches and expansion of commercial operations.
The most recent analyst rating on (TNON) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Tenon Medical, Inc. stock, see the TNON Stock Forecast page.
Spark’s Take on TNON Stock
According to Spark, TipRanks’ AI Analyst, TNON is a Neutral.
Tenon Medical, Inc. shows strong revenue growth and strategic progress, but faces significant challenges with profitability and cash flow. The technical indicators are positive, suggesting potential for stock appreciation, but the negative valuation metrics and ongoing losses weigh heavily on the overall score.
To see Spark’s full report on TNON stock, click here.
More about Tenon Medical, Inc.
Tenon Medical, Inc., established in 2012, is a medical device company specializing in the development of innovative solutions for sacro-pelvic disorders. Their flagship product, the Catamaran SI Joint Fusion System, offers a minimally invasive approach to stabilizing the SI joint using a titanium implant. The company focuses on primary SI joint procedures, revision of failed implants, and augmenting spinal fusion.
Average Trading Volume: 485,483
Technical Sentiment Signal: Sell
Current Market Cap: $10.15M
See more insights into TNON stock on TipRanks’ Stock Analysis page.